Court of Appeals for the D.C. Circuit November 29, 1996, 96-5257 (In Re: David A. Kessler, M.D.)

Also known as

United States · · · 29-11-1996

Opinion for the Court filed by Circuit Judge SILBERMAN.

SILBERMAN, Circuit Judge:

David A Kessler, M.D., the Commissioner of the Food and Drug Administration (FDA), petitions for a writ of mandamus directing the district court to vacate its order authorizing a notice of his deposition and to enter a protective order prohibiting his deposition. We conclude that mandamus is unavailable and, accordingly, we deny the petition without reviewing the district court’s order.

I.

Washington Legal Foundation, respondent here and plaintiff below, filed suit in the district court against Dr. Kessler, the FDA, and the Department of Health and Human Services, alleging that the FDA’s policies and practices with respect to the promotion of “off-label”

1

uses of FDA-approved drugs and medical devices are unconstitutional. Respondent’s theory is that the FDA is discouraging (without a formal regulation) the dissemination of information regarding off-label uses of approved products and by so doing is violating the First Amendment. Commis

*1016

sioner Kessler is alleged to be playing the key role in this initiative.

As part of discovery, respondent served a deposition notice on Dr. Kessler, claiming that his personal testimony is essential to determine the existence, genesis, and parameters of the FDA’s policy. The government moved to vacate the deposition notice on the ground that, as a senior government official, Dr. Kessler should not be deposed absent “extraordinary circumstances.”

See Simplex Time Recorder Co. v. Secretary of Labor,

766 F.2d 575, 586 (D.C.Cir.1985). The government contended that Dr. Kessler did not have unique, relevant, first-hand knowledge of pertinent information that could not be obtained from another source (several of Dr. Kessler’s subordinates were offered in his stead),

see id.,

and that to inquire into his personal deliberations or actions with respect to FDA policy is improper,

see United States v. Morgan,

313 U.S. 409, 61 S.Ct. 999, 85 L.Ed.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.